- Home
- Products
- Customized ADCs
- CD74
- Anti-CD74-hindered disulfide-Doxorubicin ADC
Anti-CD74-hindered disulfide-Doxorubicin ADC (CAT#: ADC-W-378)
This ADC product is comprised of an anti-CD74 monoclonal antibody conjugated via a hindered disulfide linker to a Doxorubicin. The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, doxorubicin binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CD74
- Alternative Names
- CD74; CD74 molecule, major histocompatibility complex, class II invariant chain; II; DHLAG; HLADG; Ia-GAMMA; HLA class II histocompatibility antigen gamma chain; p33; HLA-DR-gamma; MHC HLA-DR gamma chain; Ia-associated invariant chain; gamma chain of clas
- Target Entrez Gene ID
- 972
- Target UniProt ID
- P04233
- Overview
- The protein encoded by this gene associates with class II major histocompatibility complex (MHC) and is an important chaperone that regulates antigen presentation for immune response. It also serves as cell surface receptor for the cytokine macrophage migration inhibitory factor (MIF) which, when bound to the encoded protein, initiates survival pathways and cell proliferation. This protein also interacts with amyloid precursor protein (APP) and suppresses the production of amyloid beta (Abeta). Multiple alternatively spliced transcript variants encoding different isoforms have been identified.
- Overview
- Humanized Anti-CD74 Antibody
- Species Reactivity
- Human
- Name
- hindered disulfide
- Name
- doxorubicin
- Description
- Doxorubicin is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-378. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-039 | Anti-CD74-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2551 | Anti-CD74-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2548 | Anti-CD74-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2553 | Anti-CD74-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-036 | Anti-CD74-VC-MMAE ADC-1 | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-504 | Anti-EGFR (cetuximab)-SMCC-Doxorubicin ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | Doxorubicin |
| ADC-W-581 | Anti-EpCAM-hydrazone-Doxorubicin ADC-2 | acid-cleavable hydrazone linker | doxorubicin |
| ADC-W-502 | Anti-EGFR-SMCC-Dox ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | Doxorubicin |
| ADC-W-503 | Anti-EGFR-EDC/NHS-Dox ADC | EDC/NHS(1-ethyl-3-(3-diaminopropyl)carbodiimide/N-hydroxysuccinimide) | Doxorubicin |
| ADC-W-600 | Anti-EGFR-doxorubicin ADC | polyethylene glycol linker | doxorubicin |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD4 (Keliximab)-SPDB-DM4 ADC (CAT#: ADC-W-867)
- Anti-ITGA4 (Natalizumab)-SPDB-DM4 ADC (CAT#: ADC-W-1467)
- Anti-S. aureus ClfA (Tefibazumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2136)
- Anti-CD3E (Catumaxomab)-SPDB-DM4 ADC (CAT#: ADC-W-2271)
- Anti-MUC16 (Igovomab)-SPDB-DM4 ADC (CAT#: ADC-W-1641)
- Anti-Endotoxin (Edobacomab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2189)
- Anti-APP (Ponezumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-713)
- Anti-EGFR (MAb806)-Mal-dPEG4-NHS-DM1 ADC (CAT#: ADC-W-393)
- Anti-TNFRSF13B (Tabalumab)-SMCC-DM1 ADC (CAT#: ADC-W-1904)
- Anti-TGFB2 (Lerdelimumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1811)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.